Sage Therapeutics Inc. climbed the most in two months after the U.S. Food and Drug Administration approved an expedited development plan for what the company says could be a practice-changing depression treatment.
The biotechnology company only has to run a single 450-patient trial, which will allow for a compact, reasonably cost-efficient program that can assure both safety and effectiveness,....More>>>
Stocks rose in the first hour of the session today but lost ground steadily after that. The Dow Jones Industrial Average (DJINDICES:^DJI) and the S&P 500 (SNPINDEX:^GSPC) both had significant losses.
Today’s stock market
Index Percentage Change Point Change
Dow (0.68%) (165.52)
S&P 500 (0.86%) (23.43)
Data source: Yahoo! Finance.
Recently, Madrigal Pharmaceuticals (MDGL) announced that it had met both liver biopsy based endpoints for its phase 2 non-alcoholic steatohepatitis (NASH) study. This opens up the opportunity for the company to move on to a phase 3 study with more patients to confirm its findings. Seeing as it was able to hit both endpoints I believe that it becomes a good biotech to own. For that reason, I believe....More>>>
Recently, MEI Pharma (MEIP) announced that it had entered into a private placement agreement totaling $75 million. This new financing deal will help lead the biotech to soon have two pivotal registration studies ongoing. I believe that this biotech offers plenty of upside opportunity. Now that it has its funding in order, all that remains is to achieve positive results in the two late-stage studies.....More>>>
Cibc Bank USA lowered its holdings in shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) by 40.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 12,000 shares of the biotechnology company’s stock after selling 8,000 shares during the period. Cibc Bank USA’s holdings in REDHILL BIOPHAR/S were worth $106,000 at the end of the most recent quarter.
Separately, 683 Capital....More>>>
Five IPOs are expected to price this coming week, aiming to raise a combined total of $658 million in proceeds. US-based tech companies have delivered some of the strongest returns this year and two are scheduled for this week: Elastic and Upwork. The rest the week features a sizable biotech, one high-growth diagnostics company and a micro-cap car rental app. One healthcare-focused black check company....More>>>
Zacks Investment Research upgraded shares of ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) from a sell rating to a hold rating in a research report report published on Friday.
According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory....More>>>
Krystal Biotech (NASDAQ:KRYS) and Coherus Biosciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.
Insider & Institutional Ownership
Get Krystal Biotech alerts:....More>>>
NanoString Technologies Inc (NASDAQ:NSTG) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. NanoString Technologies Inc is a biotechnology company. It develops, manufactures and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue. NanoString Technologies Inc has a market cap of $916.930 million;....More>>>
Trexquant Investment LP raised its stake in shares of ImmunoGen (NASDAQ:IMGN) by 190.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 331,215 shares of the biotechnology company’s stock after buying an additional 217,244 shares during the quarter. Trexquant Investment LP owned about 0.25% of ImmunoGen worth $3,484,000....More>>>
Shares of Verastem (NASDAQ:VSTM) are up 16% in late-day trading on Friday after the company announced yesterday after the bell that it was selling 7,166,666 shares at $6 per share, grossing the biotech approximately $43 million.
Share prices typically — though clearly not always — go down after a secondary offering is announced, since current....More>>>
Quantitative Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,931 shares of the biotechnology company’s stock, valued at approximately $100,000.
Several other large investors also recently added....More>>>
Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”
Image source: Getty Images.
In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>
The meteoric run up in cryptocurrency valuations last year looked every bit a speculative bubble as the dot-com craze 20 years ago, and the subsequent implosion of valuations in the months since has deepened the parallels. A recent Bloomberg story noted that hundreds of virtual coins have gone to practically zero in value as the market crashed.
Although some tokens will continue to offer....More>>>
The short interest data are out for the most recent settlement date, June 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies.....More>>>